

Summary of Changes to the Alberta Human Services Drug Benefit Supplement

Effective April 1, 2020

Alberta  Human Services

Inquiries should be directed to:

Pharmacy Services

Alberta Blue Cross
10009 108 Street NW
Edmonton AB T5J 3C5

Telephone Number: (780) 498-8370 (Edmonton)
(403) 294-4041 (Calgary)
1-800-361-9632 (Toll Free)

FAX Number: (780) 498-8406
1-877-305-9911 (Toll Free)

Website: <https://www.alberta.ca/alberta-supports.aspx>

Administered by Alberta Blue Cross
on behalf of Alberta Health.

The Drug Benefit List (DBL) is a list of drugs for which coverage may be provided to program participants. The DBL is not intended to be, and must not be used as a diagnostic or prescribing tool. Inclusion of a drug on the DBL does not mean or imply that the drug is fit or effective for any specific purpose. Prescribing professionals must always use their professional judgment and should refer to product monographs and any applicable practice guidelines when prescribing drugs. The product monograph contains information that may be required for the safe and effective use of the product.

Copies of the *Alberta Drug Benefit List* are available from Pharmacy Services, Alberta Blue Cross at the address shown above.

Binder and contents: **\$42.00** (\$40.00 + \$2.00 G.S.T.)
Contents only: **\$36.75** (\$35.00 + \$1.75 G.S.T.)

A cheque or money order must accompany the request for copies.

Table of Contents

Least Cost Alternative (LCA) Price Change(s)	1
Product(s) with a Price Change	1
Discontinued Products	1
Product(s) Removed from the HSDBS as Price Policy Requirements not Satisfied	2

Least Cost Alternative (LCA) Price Change(s)

The following established IC Grouping(s) are affected and a revised LCA price has been established. Groupings affected by a price decrease, will be effective May 1, 2020. Groupings affected by a price increase, will be effective April 1, 2020.

Please review the online Alberta Drug Benefit List at https://www.ab.bluecross.ca/dbl/idbl_main1.php for further information.

<u>Generic Description</u>	<u>Strength / Form</u>	<u>New LCA Price</u>
RIZATRIPTAN BENZOATE	5 MG DISINTEGRATING TABLET	2.9633
RIZATRIPTAN BENZOATE	10 MG DISINTEGRATING TABLET	2.9633

Product(s) with a Price Change

The following product(s) had a Price Decrease. The previous higher price will be recognized until April 30, 2020. For products within an established IC Grouping, the LCA price may apply.

<u>Trade Name / Strength / Form</u>	<u>Generic Description</u>	<u>DIN</u>	<u>MFR</u>
ACCEL-RIZATRIPTAN ODT 5 MG DISINTEGRATING TABLET	RIZATRIPTAN BENZOATE	00002483270	ACP
ACCEL-RIZATRIPTAN ODT 10 MG DISINTEGRATING TABLET	RIZATRIPTAN BENZOATE	00002483289	ACP
GLUCERNA ORAL LIQUID	NUTRITIONAL PRODUCT (DIABETIC)	0000999940	ABN
PEDIASURE ORAL LIQUID	NUTRITIONAL PRODUCT (PEDIATRIC)	0000999933	ABN
PEDIASURE FIBRE ORAL LIQUID	NUTRITIONAL PRODUCT (PEDIATRIC)	0000990029	ABN
PEDIASURE PLUS WITH FIBRE ORAL LIQUID	NUTRITIONAL PRODUCT (PEDIATRIC)	0000999434	ABN
SIMILAC ALIMENTUM ORAL POWDER	INFANT FORMULA	0000999788	ABN

Discontinued Listing(s)

Notification of discontinuation has been received from the manufacturers. The Alberta government-sponsored drug programs previously covered the following drug product(s). Effective April 1, 2020, the listed product(s) will no longer be a benefit and will not be considered for coverage by special authorization. A transition period will be applied and, as of May 1, 2020 claims will no longer pay for these products.

<u>Trade Name / Strength / Form</u>	<u>Generic Description</u>	<u>DIN</u>	<u>MFR</u>
DECAXIL DROPS 400 UNIT / ML ORAL LIQUID	VITAMIN D3	00080041145	JPC
DECAXIL LIQUID 400 UNIT / ML ORAL LIQUID	VITAMIN D3	00080038155	JPC
PMS-FLUCONAZOLE 150 MG CAPSULE	FLUCONAZOLE	00002282348	PMS

Product(s) Removed from the HSDBS as Price Policy Requirements not Satisfied

The Alberta government-sponsored drug programs previously covered the following drug product(s). Effective April 1, 2020, the listed product(s) will no longer be a benefit and will not be considered for coverage by special authorization. A transition period will be applied and, as of May 1, 2020 claims will no longer pay for these products.

<u>Trade Name / Strength / Form</u>	<u>Generic Description</u>	<u>DIN</u>	<u>MFR</u>
LAX-A NEMA 10.4 G / 3.9 G RECTAL ENEMA	SODIUM PHOSPHATE/ SODIUM ACID PHOSPHATE	00002096900	PPH